Medical Outreach Program
Medical Outreach Program
The MMOP (MSD Medical Outreach Program) marks its 60th year in 2018. The MMOP is the primary means through which the company donates its pharmaceuticals and vaccines for humanitarian assistance in the developing world and in support of disaster relief worldwide.
Managed by our Office of Corporate Responsibility, the MMOP is one mechanism through which we help to expand access to our products, particularly in developing countries. Through this program, we donate pharmaceuticals and vaccines to a limited number of qualified, U.S.-based nongovernmental organization (NGO) partners. The scope of the program varies from year to year and is influenced by changing medical needs in developing countries, the quantity of our medicines available for donation, and the unpredictable nature of emergencies or disasters.
Donations of our medicines are made primarily through these qualified NGOs:
Each NGO has a long-standing relationship with the company, demonstrates integrity of purpose, provides assurance that our products will be securely warehoused, and has well-established programs for the ill and needy in developing countries. With each participating NGO, we maintain a contract designed to ensure the proper distribution and handling of our medicines, as well as to outline procedures for reporting potential adverse reactions. The contract also follows the World Health Organization (WHO) Guidelines for Drug Donations, which establish quality-assurance standards for responsible product donations. For example, we donate only products with adequate dating to ensure that they can be administered appropriately prior to their expiration date.
The MMOP comprises three components:
ANNUAL ALLOTMENT PROGRAM
Each year, the participating NGOs can order fully dated medicines of their choice from the company’s current product line, up to an annually authorized amount. Through this approach, the partners can receive a sustained and predictable supply of needed medicines, crucial to the effective planning of ongoing humanitarian programs. The most commonly requested medicines help treat diabetes, high blood pressure, and fungal or bacterial infections in developing countries where people don’t otherwise have access to these medications.
ONGOING DONATIONS OF PHARMACEUTICALS & VACCINES
Donations of our pharmaceuticals and vaccines are also made throughout the year in response to requests from our partners to address some additional needs of specific programs around the world. We also offer products to our partners proactively, based on available supply, for use in their ongoing humanitarian programs.
DISASTER & EMERGENCY RELIEF
Through the MMOP, we may also donate pharmaceuticals and vaccines in response to, or in preparation for, major disasters and emergency recovery efforts. We respond to those requests based on the relief agency’s firsthand assessment of need. We also may provide financial support for our NGO partners’ disaster-relief efforts when appropriate.
Beyond donated medicines, we seek ways to add value to our NGO partner organizations by providing both financial assistance and technical support. Beginning in 2016, the company has awarded yearly operational cash grants to assist with shipping and logistics. In addition, in 2018, to commemorate the 60th anniversary of the program, the company awarded $300,000 ($60,000 each) in cash grants to our NGO partners for general operations and capacity-building efforts.
Finally, we conduct periodic, collaborative site assessments of our NGO partners’ warehouse facilities to strengthen their overall operations and optimize supply chain effectiveness. Collaborative site assessments occur every five years or less, depending on whether previous assessments have resulted in recommended corrective actions to address measures to improve the safety, security and storage of our medicine. Such recommendations have included enhancing storage-rack inspection and maintenance, strengthening delivery receipt procedures, and improving material-handling procedures.
We are also a member of the Partnership for Quality Medical Donations (PQMD), an alliance of NGOs and medical product manufacturers dedicated to raising the standards of medical donations in order to meet the needs of underserved populations and disaster victims around the world. Members of PQMD are committed to bringing measurable health impact by setting quality standards, disseminating knowledge and influencing policy.
Throughout 2017, the donations of our medicines and vaccines provided immediate and ongoing assistance to those affected by hurricanes, earthquakes and other disasters in Mexico, Peru, the Caribbean, and the United States (including Puerto Rico and the U.S. Virgin Islands). In addition, we supported partner emergency preparedness and medical mission programs, and supplied medical aid to hundreds of thousands of people in need through the disaster response and ongoing medical programs of the NGOs with which we work. Our product donation program enabled our NGO partners to help local health care workers in developing countries treat chronic conditions and acute diseases through community health services worldwide.
|MEDICAL OUTREACH PROGRAM (MMOP)||2013||2014||2015||2016||2017|
|Countries and territories reached by the MMOP||86||91||72||55||62|
|Estimated number of people reached1, 2||NA||433,624||78,555||109,398||376,304|
|Disaster relief (product) contributions (in millions)3||$2.40||$8.50||$4.70||$13.41||$19.91|
|1. Estimated figures, which assume all product reached patients, are based on converting volume of medicines and vaccines donated in 2017. Conversion factors for this estimate were developed using a combination of QuintilesIMS SMART Data and U.S. product information found on our company’s product website.|
2. Inhalation brands were analyzed differently in 2017 as compared to previous years. Prescriber Information dosing information was used to calculate total doses for one year for chronic asthma patient and assumes splitting inhalers.
3. We set the value of our product donations based on the U.S. wholesale acquisition cost.